

## Literatur

# Indikationsfindung in der Implantologie bei Antiresorptivtherapie

Dr. Tim F. Wolff MSc., Prof. Dr. Dr. Christian Walter, Prof. Dr. Dr. Knut A. Grötz

- [1] Marx, R.E., *Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of jaws: a growing epidemic*. J Oral Maxillofac Surg, 2003. **61**(9): p. 1115-1117.
- [2] Walter, C., et al. *Zahnimplantate bei medikamentöser Behandlung mit Knochenantiresorptiva (inkl. Bisphosphonate) - S3-Leitlinie (Langversion), Stand: Juli 2016*. 2016; Available from: <http://www.awmf.org/leitlinien/detail/ll/083-026.html>.
- [3] Groetz, K.A., J.-U. Piesold, and B. Al-Nawas, *S3-Leitlinie: Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamenten-assoziierte Kiefernekrosen*. AWMF 007-091, 2012.
- [4] Smith, M.R., et al., *Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial*. Lancet, 2012. **379**(9810): p. 39-46.
- [5] Qi, W.X., et al., *Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials*. Int J Clin Oncol, 2014. **19**(2): p. 403-10.
- [6] von Moos, R., *Bisphosphonate treatment recommendations for oncologists*. Oncologist, 2005. **10 Suppl 1**: p. 19-24.
- [7] Arantes, H.P., A.G. Silva, and M. Lazaretti-Castro, *Bisphosphonates in the treatment of metabolic bone diseases*. Arq Bras Endocrinol Metabol, 2010. **54**(2): p. 206-12.
- [8] zm-online. *Rote-Hand-Brief für Zaltrap*. 2016; Available from: [http://www.zm-online.de/hefte/Rote-Hand-Brief-fuer-Zaltrap\\_344687.html](http://www.zm-online.de/hefte/Rote-Hand-Brief-fuer-Zaltrap_344687.html).
- [9] Pilanci, K.N., et al., *Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?* Medicine (Baltimore), 2015. **94**(18): p. e671.
- [10] Ponzetti, A., et al., *Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district*. Tumori, 2015. **0**(0): p. 0.
- [11] Ruggiero, S.L., et al., *Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases*. J Oral Maxillofac Surg, 2004. **62**(5): p. 527-34.
- [12] Ruggiero, S.L., et al., *American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update*. J Oral Maxillofac Surg, 2009. **67**(5 Suppl): p. 2-12.
- [13] Guarneri, V., et al., *Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer*. Breast Cancer Res Treat, 2010. **122**(1): p. 181-8.
- [14] Christodoulou, C., et al., *Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone*. Oncology, 2009. **76**(3): p. 209-11.
- [15] Walter, C., et al., *Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells*. Clin Oral Investig, 2009.
- [16] Hagelauer, N., et al., *Bisphosphonates inhibit cell functions of HUVECs, fibroblasts and osteogenic cells via inhibition of protein geranylgeranylation*. Clin Oral Investig, 2015. **19**(5): p. 1079-91.

- [17] Hagelauer, N., et al., *In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes*. Clin Oral Investig, 2015. **19**(1): p. 139-48.
- [18] Saia, G., et al., *Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction*. J Oral Maxillofac Surg, 2010. **68**(4): p. 797-804.
- [19] Tsao, C., et al., *Oral health risk factors for bisphosphonate-associated jaw osteonecrosis*. J Oral Maxillofac Surg, 2013. **71**(8): p. 1360-6.
- [20] Pushalkar, S., et al., *Oral microbiota and host innate immune response in bisphosphonate-related osteonecrosis of the jaw*. Int J Oral Sci, 2014. **6**(4): p. 219-26.
- [21] Thumbigere-Math, V., et al., *Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw*. J Periodontol, 2014. **85**(2): p. 226-33.
- [22] Walter, C., C. Laux, and K. Sagheb, *Radiologic bone loss in patients with bisphosphonate-associated osteonecrosis of the jaws: a case-control study*. Clin Oral Investig, 2014. **18**(2): p. 385-90.
- [23] Walter, C., et al., *Dental implants in patients treated with antiresorptive medication - a systematic literature review*. Int J Implant Dent, 2016. **2**(1): p. 9.
- [24] Walter, C., et al., *Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients*. Head Face Med, 2010. **6**(1): p. 11.
- [25] Walter, C., et al., *Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate*. Eur Urol, 2008. **54**(5): p. 1066-72.
- [26] Rahimi-Nedjat, R.K., et al., *Diabetes Mellitus and Its Association to the Occurrence of Medication-Related Osteonecrosis of the Jaw*. Dentistry Journal, 2016. **4**(2): p. 1-7.
- [27] Groetz, K.A. and B. Al-Nawas. *Laufzettel Biophosphonate Risiko-Evaluation bei antiresorptiver Therapie vor Implantation*. 2013; Available from: <https://www.dginet.de/web/dgi/laufzettel-bisphosphonate>.